Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.86 USD
Change Today +0.016 / 1.90%
Volume 23.4K
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

dara biosciences inc (DARA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/15 - $1.05
52 Week Low
05/15/15 - $0.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DARA BIOSCIENCES INC (DARA)

Related News

No related news articles were found.

dara biosciences inc (DARA) Related Businessweek News

No Related Businessweek News Found

dara biosciences inc (DARA) Details

DARA BioSciences, Inc., a specialty pharmaceutical company, focuses on commercialization of oncology treatment and supportive care pharmaceutical products in the United States. The company’s products comprise Soltamox, an oral solution for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups; Gelclair, an oral gel for the treatment of oral mucositis; Bionect for the management of irritation of the skin, as well as first and second degree burns; Ferralet 90 for treatment of anemia; and Aquoral for treatment of cancer. Its clinical development products include KRN5500, a novel, non-narcotic/non-opioid intravenous product for the treatment of cancer patients with painful chronic chemotherapy induced peripheral neuropathy, which has completed Phase 2a development. The company was incorporated in 2002 and is headquartered in Raleigh, North Carolina.

15 Employees
Last Reported Date: 03/3/15
Founded in 2002

dara biosciences inc (DARA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $464.4K
Executive Chairman and Chief Medical Officer
Total Annual Compensation: $487.5K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

dara biosciences inc (DARA) Key Developments

DARA BioSciences, Inc Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:00 AM

DARA BioSciences, Inc Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:00 AM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Christopher G. Clement, Chief Executive Officer, President and Director.

DARA BioSciences, Inc Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Revenue Guidance for the Full Year of 2015

DARA BioSciences Inc. announced earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net product revenues of $990,800 compared to $409,400 a year ago. Net loss attributable to controlling interest was $2,684,100 or $0.14 per share compared to $2,583,100 or $0.24 per share a year ago. The increase in Revenue was primarily attributable to the expanded commercial sales organization and ongoing success in generating interest and prescriptions across DARA's oncology supportive care product portfolio. The loss attributable to controlling interest for the current quarter was $101,000 more than the same period last year. For the six months, the company reported net product revenues of $1,643,000 compared to $570,900 a year ago. Net loss attributable to controlling interest was $5,835,200 compared to $5,241,100 a year ago. Based on current trends and continued growth DARA continues to support previous guidance of $3.7 million for Gelclair and Soltamox net sales for the full year 2015, excluding any net revenue contribution from the launch of Oravig later in the year.

DARA BioSciences, Inc to Report Q2, 2015 Results on Aug 12, 2015

DARA BioSciences, Inc announced that they will report Q2, 2015 results After-Market on Aug 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DARA:US $0.86 USD +0.016

DARA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $4.31 USD +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation DARA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DARA BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at